$TNDM,,Good news/Bad news with this stock. Price l
Post# of 22756
(Total Views: 263)
Posted On: 05/30/2017 7:31:48 PM
$TNDM,,Good news/Bad news with this stock. Price looks to be at bottom and the charts shows some signs of upward reversal may be expected. The information below has both good and bad news but me being the optimist, I believe more good news is observed. $.80 was support but price broke that down a couple of times during the last 5 days, and now it is 1st line resistance. I will keep my eyes on this and if it can stay over $.82 AND get some volume,,,I will be a buyer.
FROM FRIDAY:
The medical device company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.09. Tandem Diabetes Care had a negative net margin of 95.57% and a negative return on equity of 220.14%. The business had revenue of $17.50 million for the quarter, compared to analysts’ expectations of $15.72 million. During the same period in the prior year, the company posted ($0.68) EPS. The firm’s revenue was down 12.9% on a year-over-year basis.
Several research firms have recently weighed in on TNDM. B. Riley reissued a “neutral” rating and issued a $1.50 price target on shares of Tandem Diabetes Care in a research note on Wednesday, May 3rd. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a report on Tuesday, March 14th. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Tandem Diabetes Care in a report on Thursday, March 30th. Cowen and Company lowered shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and set a $1.50 target price on the stock. in a report on Monday, April 10th. Finally, Northcoast Research restated a “buy” rating on shares of Tandem Diabetes Care in a report on Thursday, March 9th. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Tandem Diabetes Care presently has an average rating of “Hold” and a consensus target price of $4.71.
In related news, CEO Kim D. Blickenstaff acquired 1,600,000 shares of Tandem Diabetes Care stock in a transaction that occurred on Thursday, March 23rd. The stock was purchased at an average price of $1.25 per share, for a total transaction of $2,000,000.00. Following the completion of the purchase, the chief executive officer now directly owns 2,007,939 shares of the company’s stock, valued at $2,509,923.75. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 37.10% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in TNDM. Frontier Capital Management Co. LLC increased its stake in shares of Tandem Diabetes Care by 348.5% in the first quarter. Frontier Capital Management Co. LLC now owns 4,901,870 shares of the medical device company’s stock worth $5,882,000 after buying an additional 3,808,950 shares during the period. Vanguard Group Inc. increased its stake in shares of Tandem Diabetes Care by 181.1% in the first quarter. Vanguard Group Inc. now owns 1,200,616 shares of the medical device company’s stock worth $1,441,000 after buying an additional 773,475 shares during the period. Bank of America Corp DE increased its stake in shares of Tandem Diabetes Care by 88.6% in the first quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock worth $1,032,000 after buying an additional 404,452 shares during the period. Paulson & CO. Inc. purchased a new stake in shares of Tandem Diabetes Care during the first quarter worth approximately $600,000. Finally, Granite Investment Partners LLC increased its stake in shares of Tandem Diabetes Care by 29.9% in the first quarter. Granite Investment Partners LLC now owns 448,921 shares of the medical device company’s stock worth $539,000 after buying an additional 103,365 shares during the period. Institutional investors own 56.79% of the company’s stock.
The stock’s market capitalization is $41.74 million. The company has a 50 day moving average price of $0.96 and a 200 day moving average price of $1.86.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
FROM FRIDAY:
The medical device company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.09. Tandem Diabetes Care had a negative net margin of 95.57% and a negative return on equity of 220.14%. The business had revenue of $17.50 million for the quarter, compared to analysts’ expectations of $15.72 million. During the same period in the prior year, the company posted ($0.68) EPS. The firm’s revenue was down 12.9% on a year-over-year basis.
Several research firms have recently weighed in on TNDM. B. Riley reissued a “neutral” rating and issued a $1.50 price target on shares of Tandem Diabetes Care in a research note on Wednesday, May 3rd. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a report on Tuesday, March 14th. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Tandem Diabetes Care in a report on Thursday, March 30th. Cowen and Company lowered shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and set a $1.50 target price on the stock. in a report on Monday, April 10th. Finally, Northcoast Research restated a “buy” rating on shares of Tandem Diabetes Care in a report on Thursday, March 9th. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Tandem Diabetes Care presently has an average rating of “Hold” and a consensus target price of $4.71.
In related news, CEO Kim D. Blickenstaff acquired 1,600,000 shares of Tandem Diabetes Care stock in a transaction that occurred on Thursday, March 23rd. The stock was purchased at an average price of $1.25 per share, for a total transaction of $2,000,000.00. Following the completion of the purchase, the chief executive officer now directly owns 2,007,939 shares of the company’s stock, valued at $2,509,923.75. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 37.10% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in TNDM. Frontier Capital Management Co. LLC increased its stake in shares of Tandem Diabetes Care by 348.5% in the first quarter. Frontier Capital Management Co. LLC now owns 4,901,870 shares of the medical device company’s stock worth $5,882,000 after buying an additional 3,808,950 shares during the period. Vanguard Group Inc. increased its stake in shares of Tandem Diabetes Care by 181.1% in the first quarter. Vanguard Group Inc. now owns 1,200,616 shares of the medical device company’s stock worth $1,441,000 after buying an additional 773,475 shares during the period. Bank of America Corp DE increased its stake in shares of Tandem Diabetes Care by 88.6% in the first quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock worth $1,032,000 after buying an additional 404,452 shares during the period. Paulson & CO. Inc. purchased a new stake in shares of Tandem Diabetes Care during the first quarter worth approximately $600,000. Finally, Granite Investment Partners LLC increased its stake in shares of Tandem Diabetes Care by 29.9% in the first quarter. Granite Investment Partners LLC now owns 448,921 shares of the medical device company’s stock worth $539,000 after buying an additional 103,365 shares during the period. Institutional investors own 56.79% of the company’s stock.
The stock’s market capitalization is $41.74 million. The company has a 50 day moving average price of $0.96 and a 200 day moving average price of $1.86.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
(1)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
Scroll down for more posts ▼